Meduloc closed a $4 million Series B led by GenHenn Capital to launch its fracture-fixation platform and build clinical and commercial infrastructure.
- Amount
- $4M
- Stage
- Series B
- Announced
- 6 August 2026
- Lead
- GenHenn Capital
- Other investors
- Life Sciences Greenhouse Investments, Ben Franklin Technology Partners of Southeastern Pennsylvania, Broad Street Angels, Andre Ethier
- Use of funds
- Controlled alpha launch, continued clinical evidence generation, and commercial infrastructure development.
- Checked
- Announced by the company